This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BioVie’s 8K filing here.
About BioVie
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
See Also
- Five stocks we like better than BioVie
- Industrial Products Stocks Investing
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Basic Materials Stocks Investing
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Calculate Return on Investment (ROI)
- Tesla Stock: Buy the Dips, Sell the Rips
